Hong Kong · Delayed Price · Currency is HKD CStone Pharmaceuticals Company Description
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis.
Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma.
The company’s products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases.
CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
| Country | Cayman Islands |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Jianxin Yang |
Contact Details
Address: C1 Building Suzhou, 215123 China | |
| Phone | 86 512 8718 6550 |
| Website | cstonepharma.com |
Stock Details
| Ticker Symbol | 2616 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG2588M1006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jianxin Yang M.D., Ph.D. | Chief Executive Officer, President of Research & Development and Executive Director |
| Weicong Ni | Chief Financial Officer and Joint Company Secretary |
| Ying Hua Zhang | Senior Vice President and Chief Operating Officer |
| Michael J. Choi M.B.A. | Chief Business and Strategy Officer |
| Dr. Yujuan La Ph.D. | Senior Vice President of Product Development |
| Dr. Qingmei Shi M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Mei Yee Yung FCIS, FCS | Joint Company Secretary |